ACADIA Initiates Phase II Trial with Pimavanserin for Alzheimer's Disease Psychosis

Loading...
Loading...
ACADIA Pharmaceuticals
ACAD
today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis (ADP). No drug is approved in the United States to treat ADP and the off-label use of current antipsychotics is linked to increased mortality, serious adverse events, and cognitive decline in elderly patients with dementia-related psychosis. “The development of psychosis and related behavioral disturbances in patients with Alzheimer's disease carries a poor prognosis and often has
See full press release
Posted In: NewsGuidanceOfferingsContractsManagementGlobal
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...